Boston Scientific Co. (NYSE:BSX) Shares Bought by L & S Advisors Inc

L & S Advisors Inc grew its stake in Boston Scientific Co. (NYSE:BSX) by 153.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 81,519 shares of the medical equipment provider’s stock after purchasing an additional 49,410 shares during the period. L & S Advisors Inc’s holdings in Boston Scientific were worth $6,831,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. Capital World Investors boosted its position in Boston Scientific by 69.9% during the first quarter. Capital World Investors now owns 16,008,085 shares of the medical equipment provider’s stock worth $1,096,394,000 after purchasing an additional 6,588,256 shares in the last quarter. Marshall Wace LLP increased its stake in Boston Scientific by 115.9% during the second quarter. Marshall Wace LLP now owns 6,720,480 shares of the medical equipment provider’s stock worth $517,544,000 after acquiring an additional 3,608,158 shares during the last quarter. Capital Research Global Investors acquired a new stake in shares of Boston Scientific in the first quarter valued at about $182,897,000. AustralianSuper Pty Ltd grew its stake in shares of Boston Scientific by 4,292.3% in the third quarter. AustralianSuper Pty Ltd now owns 2,676,847 shares of the medical equipment provider’s stock valued at $224,320,000 after buying an additional 2,615,903 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its holdings in Boston Scientific by 30.0% in the second quarter. Ameriprise Financial Inc. now owns 7,899,610 shares of the medical equipment provider’s stock valued at $608,349,000 after purchasing an additional 1,824,405 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Activity

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 132,527 shares of Boston Scientific stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $85.00, for a total value of $11,264,795.00. Following the sale, the executive vice president now owns 160,467 shares of the company’s stock, valued at $13,639,695. This trade represents a 45.23 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Michael F. Mahoney sold 162,777 shares of the firm’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $84.63, for a total value of $13,775,817.51. Following the completion of the transaction, the chief executive officer now owns 1,572,096 shares of the company’s stock, valued at $133,046,484.48. The trade was a 9.38 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 309,270 shares of company stock valued at $26,196,718 in the last 90 days. 0.50% of the stock is owned by company insiders.

Boston Scientific Trading Down 0.2 %

Shares of BSX opened at $90.17 on Thursday. Boston Scientific Co. has a 12-month low of $53.93 and a 12-month high of $91.08. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $132.90 billion, a price-to-earnings ratio of 74.52, a P/E/G ratio of 2.66 and a beta of 0.79. The stock’s 50-day moving average price is $85.71 and its 200 day moving average price is $79.92.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04. The company had revenue of $4.21 billion for the quarter, compared to the consensus estimate of $4.04 billion. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The company’s quarterly revenue was up 19.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.50 earnings per share. As a group, research analysts predict that Boston Scientific Co. will post 2.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on BSX. Evercore ISI increased their price target on Boston Scientific from $82.00 to $90.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Sanford C. Bernstein increased their target price on Boston Scientific from $92.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, October 24th. TD Cowen raised their target price on Boston Scientific from $86.00 to $100.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Mizuho lifted their target price on Boston Scientific from $100.00 to $110.00 and gave the stock an “outperform” rating in a report on Thursday, October 24th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Boston Scientific in a research report on Monday. Four research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $93.39.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.